Please assess the completion status of the following clinical trial:

Trial Title: Acetyl-L-carnitine in Combination With a Cisplatin-containing Chemotherapy as First Line Treatment of Advanced or Metastatic Non Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 18~* No previous CHT or targeted therapies. Previous adjuvant or neo-adjuvant treatment is permitted if completed ≥ 6 months before study inclusion.~* ECOG performance status 0-1~* Adequate organ functions defined as follows:~* Neutrophils ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L, and hemoglobin ≥ 9 g/dL~* Bilirubin level either normal or \< 1.5 x ULN~* ASAT and ALAT \< 2.5 x ULN (\< 5 x ULN if liver metastasis are present)~* Serum creatinine \<1.5 x ULN~* Written informed consent given before the randomization, according to International Conference on Harmonization/Good Clinical Practice (ICH/GCP)~Exclusion Criteria:~* Symptomatic brain metastases~* Any investigational agent(s) within 4 weeks prior to study entry~* Clinically relevant coronary artery disease or a history of a myocardial infarction within the last 12 months~* Acute or sub-acute intestinal occlusion or history of inflammatory bowel disease~* Patients with known allergy to any other components of the study drugs~* History or presence of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or patient at high risk from treatment complication~* Known drug abuse/ alcohol abuse~* Legal incapacity or limited legal capacity~* Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent~* Clinically relevant peripheral neuropathy~* Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ of the cervix (Patients with a previous malignancy but without evidence of disease for \< 5 years will be allowed to enter the trial)~* Pregnancy or breast feeding. Women of childbearing potential and their parents must be willing to practice acceptable methods of birth control to prevent pregnancy~* Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CHT cisplatin containing + placebo (Type: PLACEBO_COMPARATOR): None
- CHT cisplatin containing + acetyl-L-carnitina (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).